NASDAQ:ORMP - Oramed Pharmaceuticals Stock Price, Forecast & News

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) released its earnings results on Thursday, January, 9th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.11. The biotechnology company had revenue of $0.67 million for the quarter. Oramed Pharmaceuticals had a negative net margin of 297.30% and a negative return on equity of 38.51%. View Oramed Pharmaceuticals' Earnings History.

Oramed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, April 8th 2020. View Earnings Estimates for Oramed Pharmaceuticals.

2 Wall Street analysts have issued 12-month price targets for Oramed Pharmaceuticals' shares. Their forecasts range from $7.00 to $20.00. On average, they anticipate Oramed Pharmaceuticals' share price to reach $13.50 in the next twelve months. This suggests a possible upside of 241.8% from the stock's current price. View Analyst Price Targets for Oramed Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oramed Pharmaceuticals.

News headlines about ORMP stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oramed Pharmaceuticals earned a coverage optimism score of 1.5 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Oramed Pharmaceuticals.

Some companies that are related to Oramed Pharmaceuticals include Syros Pharmaceuticals (SYRS), Osmotica Pharmaceuticals (OSMT), OptiNose (OPTN), MannKind (MNKD), Aduro BioTech (ADRO), AMAG Pharmaceuticals (AMAG), Wave Life Sciences (WVE), Kamada (KMDA), Gemphire Therapeutics (GEMP), Hookipa Pharma (HOOK), BIOFRONTERA AG/ADR (BFRA), Kalvista Pharmaceuticals (KALV), Seres Therapeutics (MCRB), MEI Pharma (MEIP) and Protagonist Therapeutics (PTGX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), Zynerba Pharmaceuticals (ZYNE), Gilead Sciences (GILD), Novavax (NVAX), Pluristem Therapeutics (PSTI), NovaBay Pharmaceuticals (NBY) and Corbus Pharmaceuticals (CRBP).

Oramed Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.28%), Marshall Wace LLP (0.64%) and Jane Street Group LLC (0.21%). Company insiders that own Oramed Pharmaceuticals stock include Aviad Friedman, Leonard Sank and Nadav Kidron. View Institutional Ownership Trends for Oramed Pharmaceuticals.

ORMP stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Renaissance Technologies LLC and Jane Street Group LLC. Company insiders that have bought Oramed Pharmaceuticals stock in the last two years include Aviad Friedman and Leonard Sank. View Insider Buying and Selling for Oramed Pharmaceuticals.

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ORMP stock can currently be purchased for approximately $3.95.

Oramed Pharmaceuticals has a market capitalization of $70.26 million and generates $2.70 million in revenue each year. The biotechnology company earns $-14,350,000.00 in net income (profit) each year or $0.82 on an earnings per share basis. View Additional Information About Oramed Pharmaceuticals.

The official website for Oramed Pharmaceuticals is http://www.oramed.com/.

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]